ZA200207996B - A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines. - Google Patents
A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines. Download PDFInfo
- Publication number
- ZA200207996B ZA200207996B ZA200207996A ZA200207996A ZA200207996B ZA 200207996 B ZA200207996 B ZA 200207996B ZA 200207996 A ZA200207996 A ZA 200207996A ZA 200207996 A ZA200207996 A ZA 200207996A ZA 200207996 B ZA200207996 B ZA 200207996B
- Authority
- ZA
- South Africa
- Prior art keywords
- triene
- methyl
- diazocin
- methano
- pyrido
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims description 97
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 33
- 208000019695 Migraine disease Diseases 0.000 title claims description 29
- 230000001154 acute effect Effects 0.000 title claims description 23
- 208000004296 neuralgia Diseases 0.000 title claims description 19
- 208000021722 neuropathic pain Diseases 0.000 title claims description 19
- 208000000094 Chronic Pain Diseases 0.000 title claims description 18
- 238000000034 method Methods 0.000 claims description 90
- 239000000203 mixture Substances 0.000 claims description 86
- 230000036407 pain Effects 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 55
- 239000000730 antalgic agent Substances 0.000 claims description 48
- 230000003287 optical effect Effects 0.000 claims description 33
- 206010027599 migraine Diseases 0.000 claims description 27
- 229960002715 nicotine Drugs 0.000 claims description 25
- 239000004031 partial agonist Substances 0.000 claims description 24
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 23
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 23
- -1 anti-arrythmics Substances 0.000 claims description 21
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 20
- 208000005298 acute pain Diseases 0.000 claims description 17
- 230000001684 chronic effect Effects 0.000 claims description 16
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 210000005036 nerve Anatomy 0.000 claims description 11
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 10
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical group [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 10
- 229960001948 caffeine Drugs 0.000 claims description 10
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 10
- 239000003890 substance P antagonist Substances 0.000 claims description 10
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical group OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 9
- 229940049706 benzodiazepine Drugs 0.000 claims description 9
- 229940111134 coxibs Drugs 0.000 claims description 9
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims description 9
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 8
- 206010019233 Headaches Diseases 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 231100000869 headache Toxicity 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 8
- 239000003158 myorelaxant agent Substances 0.000 claims description 8
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
- 230000008653 root damage Effects 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 102000011040 TRPV Cation Channels Human genes 0.000 claims description 7
- 108010062740 TRPV Cation Channels Proteins 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000003193 general anesthetic agent Substances 0.000 claims description 7
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 7
- 239000000018 receptor agonist Substances 0.000 claims description 7
- 229940044601 receptor agonist Drugs 0.000 claims description 7
- DWDCLEHDNICBMI-UHFFFAOYSA-N 3-bromocytisine Chemical group C1C2CNCC1CN1C2=CC=C(Br)C1=O DWDCLEHDNICBMI-UHFFFAOYSA-N 0.000 claims description 6
- 108030001720 Bontoxilysin Proteins 0.000 claims description 6
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 6
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 6
- 102000004129 N-Type Calcium Channels Human genes 0.000 claims description 6
- 108090000699 N-Type Calcium Channels Proteins 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 230000001773 anti-convulsant effect Effects 0.000 claims description 6
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 6
- 239000001961 anticonvulsive agent Substances 0.000 claims description 6
- 229940125715 antihistaminic agent Drugs 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- 229940030600 antihypertensive agent Drugs 0.000 claims description 6
- 239000002220 antihypertensive agent Substances 0.000 claims description 6
- 150000001557 benzodiazepines Chemical class 0.000 claims description 6
- 229940053031 botulinum toxin Drugs 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 claims description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical group N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 6
- 239000000014 opioid analgesic Substances 0.000 claims description 6
- 229940005483 opioid analgesics Drugs 0.000 claims description 6
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 6
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 5
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 5
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 5
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 5
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 claims description 5
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 5
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 5
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 5
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 5
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 5
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 5
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 5
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 5
- 239000009271 Sarapin Substances 0.000 claims description 5
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 5
- 101000942305 Zea mays Cytokinin dehydrogenase 1 Proteins 0.000 claims description 5
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 5
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 5
- 229960003150 bupivacaine Drugs 0.000 claims description 5
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 claims description 5
- 229960004587 carisoprodol Drugs 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- NBGMTBMAENFSAW-UHFFFAOYSA-N chembl64496 Chemical compound C1C2CNCC1CN1C2=CC=C(Cl)C1=O NBGMTBMAENFSAW-UHFFFAOYSA-N 0.000 claims description 5
- 229960004782 chlordiazepoxide Drugs 0.000 claims description 5
- 229960002896 clonidine Drugs 0.000 claims description 5
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 5
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical group C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims description 5
- 229940119321 dantrium Drugs 0.000 claims description 5
- LTWQNYPDAUSXBC-CDJGKPBYSA-L dantrolene sodium hemiheptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1.C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1 LTWQNYPDAUSXBC-CDJGKPBYSA-L 0.000 claims description 5
- 229940026692 decadron Drugs 0.000 claims description 5
- 229960003914 desipramine Drugs 0.000 claims description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
- 229960001985 dextromethorphan Drugs 0.000 claims description 5
- 229960003529 diazepam Drugs 0.000 claims description 5
- 229960001259 diclofenac Drugs 0.000 claims description 5
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 5
- 229950005455 eliprodil Drugs 0.000 claims description 5
- 229960003976 etidocaine Drugs 0.000 claims description 5
- 229940099283 flexeril Drugs 0.000 claims description 5
- 229960002464 fluoxetine Drugs 0.000 claims description 5
- 229960001680 ibuprofen Drugs 0.000 claims description 5
- 229960003998 ifenprodil Drugs 0.000 claims description 5
- 229960000905 indomethacin Drugs 0.000 claims description 5
- 229960004502 levodopa Drugs 0.000 claims description 5
- 229960004194 lidocaine Drugs 0.000 claims description 5
- 229960004391 lorazepam Drugs 0.000 claims description 5
- 229960002009 naproxen Drugs 0.000 claims description 5
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 5
- 229960005254 naratriptan Drugs 0.000 claims description 5
- 229960001730 nitrous oxide Drugs 0.000 claims description 5
- 239000001272 nitrous oxide Substances 0.000 claims description 5
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 claims description 5
- 229960000762 perphenazine Drugs 0.000 claims description 5
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 5
- 229960004618 prednisone Drugs 0.000 claims description 5
- 229960001233 pregabalin Drugs 0.000 claims description 5
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 5
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 5
- 229960002601 protriptyline Drugs 0.000 claims description 5
- 229960000425 rizatriptan Drugs 0.000 claims description 5
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims description 5
- 229960000371 rofecoxib Drugs 0.000 claims description 5
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical group C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims description 5
- 229960001549 ropivacaine Drugs 0.000 claims description 5
- 229940120828 sarapin Drugs 0.000 claims description 5
- 229960003708 sumatriptan Drugs 0.000 claims description 5
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 5
- 229960004394 topiramate Drugs 0.000 claims description 5
- IGRXMNYYQGKFCK-UHFFFAOYSA-N trideca-2,4,6-triene Chemical compound CCCCCCC=CC=CC=CC IGRXMNYYQGKFCK-UHFFFAOYSA-N 0.000 claims description 5
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 claims description 5
- 229960002811 ziconotide Drugs 0.000 claims description 5
- 229960001360 zolmitriptan Drugs 0.000 claims description 5
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 4
- 208000004998 Abdominal Pain Diseases 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 208000008035 Back Pain Diseases 0.000 claims description 4
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 4
- HYHCJHBDDKMCTD-UHFFFAOYSA-N C1C2CNCC1CN1C2=CC=C(F)C1=O Chemical compound C1C2CNCC1CN1C2=CC=C(F)C1=O HYHCJHBDDKMCTD-UHFFFAOYSA-N 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000006561 Cluster Headache Diseases 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
- 206010015958 Eye pain Diseases 0.000 claims description 4
- 206010016059 Facial pain Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- 208000007914 Labor Pain Diseases 0.000 claims description 4
- 208000035945 Labour pain Diseases 0.000 claims description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
- 208000008930 Low Back Pain Diseases 0.000 claims description 4
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 4
- 208000000112 Myalgia Diseases 0.000 claims description 4
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 4
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 206010049002 Scar pain Diseases 0.000 claims description 4
- 208000008765 Sciatica Diseases 0.000 claims description 4
- 206010040744 Sinus headache Diseases 0.000 claims description 4
- 206010072005 Spinal pain Diseases 0.000 claims description 4
- 206010043269 Tension headache Diseases 0.000 claims description 4
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 4
- 229960004538 alprazolam Drugs 0.000 claims description 4
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical group C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960000836 amitriptyline Drugs 0.000 claims description 4
- 238000002266 amputation Methods 0.000 claims description 4
- 206010003074 arachnoiditis Diseases 0.000 claims description 4
- 229960000794 baclofen Drugs 0.000 claims description 4
- 210000000133 brain stem Anatomy 0.000 claims description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 4
- 229960000623 carbamazepine Drugs 0.000 claims description 4
- 229960000590 celecoxib Drugs 0.000 claims description 4
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 4
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 4
- 229960004126 codeine Drugs 0.000 claims description 4
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical group C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 4
- 229960004193 dextropropoxyphene Drugs 0.000 claims description 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 4
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 4
- 229960002870 gabapentin Drugs 0.000 claims description 4
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims description 4
- 229960003132 halothane Drugs 0.000 claims description 4
- 229960001410 hydromorphone Drugs 0.000 claims description 4
- 210000004086 maxillary sinus Anatomy 0.000 claims description 4
- 229960005181 morphine Drugs 0.000 claims description 4
- 208000013465 muscle pain Diseases 0.000 claims description 4
- 208000019382 nerve compression syndrome Diseases 0.000 claims description 4
- 230000008764 nerve damage Effects 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 229960002296 paroxetine Drugs 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 208000027232 peripheral nervous system disease Diseases 0.000 claims description 4
- 229960000482 pethidine Drugs 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 4
- 229960002073 sertraline Drugs 0.000 claims description 4
- 210000002027 skeletal muscle Anatomy 0.000 claims description 4
- 210000004872 soft tissue Anatomy 0.000 claims description 4
- 210000000278 spinal cord Anatomy 0.000 claims description 4
- 208000004371 toothache Diseases 0.000 claims description 4
- 229960003741 tranylcypromine Drugs 0.000 claims description 4
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 4
- 229960000604 valproic acid Drugs 0.000 claims description 4
- 208000009935 visceral pain Diseases 0.000 claims description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 3
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 3
- 229960003965 antiepileptics Drugs 0.000 claims description 3
- 210000003461 brachial plexus Anatomy 0.000 claims description 3
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960002023 chloroprocaine Drugs 0.000 claims description 3
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 3
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 3
- 229960000240 hydrocodone Drugs 0.000 claims description 3
- 239000003612 morphinomimetic agent Substances 0.000 claims description 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 3
- 208000030062 persistent idiopathic facial pain Diseases 0.000 claims description 3
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 claims description 3
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 3
- HRVMVUUOSIHXEI-UHFFFAOYSA-N C1C2CNCC1CN1C2=CC=C(CC)C1=O Chemical compound C1C2CNCC1CN1C2=CC=C(CC)C1=O HRVMVUUOSIHXEI-UHFFFAOYSA-N 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 229940080861 demerol Drugs 0.000 claims description 2
- QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 claims description 2
- 229940099212 dilaudid Drugs 0.000 claims description 2
- 229940089568 lortab Drugs 0.000 claims description 2
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims description 2
- 229960001810 meprednisone Drugs 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- AMKVXSZCKVJAGH-UHFFFAOYSA-N naratriptan Chemical compound C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AMKVXSZCKVJAGH-UHFFFAOYSA-N 0.000 claims 2
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 claims 2
- ZIWFCOIGUNPHPM-HKUYNNGSSA-N (2s,3s)-n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 ZIWFCOIGUNPHPM-HKUYNNGSSA-N 0.000 claims 1
- ROUZAASFCWDOOH-UHFFFAOYSA-N 3-[2-methoxy-5-(trifluoromethoxy)phenyl]-10-phenyl-1,9-diazaspiro[4.5]decane Chemical compound COC1=CC=C(OC(F)(F)F)C=C1C1CC2(C(NCCC2)C=2C=CC=CC=2)NC1 ROUZAASFCWDOOH-UHFFFAOYSA-N 0.000 claims 1
- CGVFPUYVFBJOCY-UHFFFAOYSA-N 6-methoxy-1-methyl-7-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2CCC(=O)N(C)C=2C=C1CNC1CCCNC1C1=CC=CC=C1 CGVFPUYVFBJOCY-UHFFFAOYSA-N 0.000 claims 1
- CKULNPVHUCWUPO-UHFFFAOYSA-N 7-methoxy-1-methyl-6-[[(2-phenylpiperidin-3-yl)amino]methyl]-3,4-dihydroquinolin-2-one Chemical compound COC1=CC=2N(C)C(=O)CCC=2C=C1CNC1CCCNC1C1=CC=CC=C1 CKULNPVHUCWUPO-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- GQVTUDRXPMPVRX-UHFFFAOYSA-N chembl62858 Chemical compound C1C2CNCC1CN1C2=CC=C(I)C1=O GQVTUDRXPMPVRX-UHFFFAOYSA-N 0.000 claims 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Substances CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims 1
- XVFCRSOWSDNUPD-UHFFFAOYSA-N n-[[2-methoxy-5-(1,1,1-trifluoro-2-methylbut-3-yn-2-yl)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(C(C)(C#C)C(F)(F)F)C=C1CNC1C(C=2C=CC=CC=2)NCCC1 XVFCRSOWSDNUPD-UHFFFAOYSA-N 0.000 claims 1
- 239000004084 narcotic analgesic agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 44
- 238000012360 testing method Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000012528 membrane Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 7
- 230000027455 binding Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000037324 pain perception Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 150000005672 tetraenes Chemical class 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 description 3
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 description 3
- 229940027564 cytisine Drugs 0.000 description 3
- 229930017327 cytisine Natural products 0.000 description 3
- 229960005426 doxepin Drugs 0.000 description 3
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 3
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 description 3
- 229960000930 hydroxyzine Drugs 0.000 description 3
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 3
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- ZUXXFRXUPFGGPW-UHFFFAOYSA-N C12=CC=C(Br)C(=O)N2CC2CN(C)CC1C2 Chemical compound C12=CC=C(Br)C(=O)N2CC2CN(C)CC1C2 ZUXXFRXUPFGGPW-UHFFFAOYSA-N 0.000 description 1
- MYEABNSFVNHLCV-UHFFFAOYSA-N C1C2CNCC1CN1C2=CC=C(C)C1=O Chemical compound C1C2CNCC1CN1C2=CC=C(C)C1=O MYEABNSFVNHLCV-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 241000208442 Sarracenia Species 0.000 description 1
- 241000208437 Sarraceniaceae Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930186949 TCA Natural products 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940072698 ativan Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006949 cholinergic function Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000009955 peripheral mechanism Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- LEGMHPGYPXPXKB-UHFFFAOYSA-N piperidin-2-ol Chemical compound OC1CCCCN1 LEGMHPGYPXPXKB-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 229940127222 serotonin uptake blocker Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 229960001124 trientine Drugs 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19573800P | 2000-04-07 | 2000-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200207996B true ZA200207996B (en) | 2003-10-20 |
Family
ID=22722582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200207996A ZA200207996B (en) | 2000-04-07 | 2002-10-04 | A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines. |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US20010036943A1 (fr) |
| EP (1) | EP1272218B1 (fr) |
| JP (1) | JP2003530345A (fr) |
| KR (1) | KR20030040201A (fr) |
| CN (1) | CN1468111A (fr) |
| AP (1) | AP2002002642A0 (fr) |
| AR (1) | AR027773A1 (fr) |
| AT (1) | ATE291438T1 (fr) |
| AU (1) | AU3768001A (fr) |
| BG (1) | BG107138A (fr) |
| BR (1) | BR0109837A (fr) |
| CA (1) | CA2405142A1 (fr) |
| CR (1) | CR6767A (fr) |
| CZ (1) | CZ20023214A3 (fr) |
| DE (1) | DE60109589T2 (fr) |
| EA (1) | EA004930B1 (fr) |
| EE (1) | EE200200579A (fr) |
| ES (1) | ES2236185T3 (fr) |
| GT (1) | GT200100055A (fr) |
| HU (1) | HUP0301822A3 (fr) |
| IL (1) | IL152076A0 (fr) |
| IS (1) | IS6560A (fr) |
| MA (1) | MA26889A1 (fr) |
| MX (1) | MXPA02009817A (fr) |
| NO (1) | NO20024734D0 (fr) |
| OA (1) | OA12241A (fr) |
| PA (1) | PA8515001A1 (fr) |
| PE (1) | PE20011307A1 (fr) |
| PL (1) | PL365957A1 (fr) |
| SK (1) | SK13952002A3 (fr) |
| SV (1) | SV2002000377A (fr) |
| TN (1) | TNSN01053A1 (fr) |
| WO (1) | WO2001076576A2 (fr) |
| YU (1) | YU74602A (fr) |
| ZA (1) | ZA200207996B (fr) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100491282B1 (ko) | 1996-07-24 | 2005-05-24 | 워너-램버트 캄파니 엘엘씨 | 통증 치료용 이소부틸가바 및 그의 유도체 |
| US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| AU2001296350A1 (en) * | 2000-09-26 | 2002-04-08 | The Brigham And Women's Hospital, Inc. | Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics |
| US7074961B2 (en) | 2000-09-26 | 2006-07-11 | The Brigham And Women's Hospital, Inc. | Antidepressants and their analogues as long-acting local anesthetics and analgesics |
| IL157881A0 (en) * | 2001-04-20 | 2004-03-28 | Pfizer Prod Inc | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds |
| EP1395289B1 (fr) * | 2001-06-07 | 2010-12-15 | Christine Dr. Sang | Traitement de la douleur nevropathique avec des antagonistes du recepteur n-methyl-d-aspartate (nmda) |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| US20040138239A1 (en) * | 2001-08-23 | 2004-07-15 | Bruce Frome | Compositions and methods for targeting cerebral circulation and treatment of headache |
| EP1419161A1 (fr) | 2001-08-24 | 2004-05-19 | PHARMACIA & UPJOHN COMPANY | Heteroaryl-7-aza 2.2.1]bicycloheptanes substitues destines au traitement de maladies |
| NZ531786A (en) | 2001-10-02 | 2006-10-27 | Upjohn Co | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| BR0214016A (pt) | 2001-11-09 | 2004-10-13 | Upjohn Co | Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr |
| US20030170326A1 (en) * | 2001-12-13 | 2003-09-11 | Council Of Scientific And Industrial Research | Bioavailability enchancing activity of Zingiber officinale Linn and its extracts/fractions thereof |
| MXPA04006882A (es) * | 2002-01-17 | 2004-12-06 | Neurogen Corp | Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina. |
| WO2003066040A1 (fr) * | 2002-02-05 | 2003-08-14 | Ajinomoto Co.,Inc. | Compositions medicinales contenant une gabapentine ou une pregabaline et antagoniste a canal de calcium de type n |
| WO2003068211A1 (fr) * | 2002-02-12 | 2003-08-21 | Cypress Bioscience, Inc. | Methodes de traitement du trouble d'hyperactivite avec deficit de l'attention (thada) |
| US6852716B2 (en) | 2002-02-15 | 2005-02-08 | Pfizer Inc | Substituted-aryl compounds for treatment of disease |
| JP2005523288A (ja) | 2002-02-19 | 2005-08-04 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド |
| AU2003217275A1 (en) | 2002-02-19 | 2003-09-09 | Pharmacia And Upjohn Company | Azabicyclic compounds for the treatment of disease |
| EP1499309A4 (fr) * | 2002-04-24 | 2008-05-28 | Cypress Bioscience Inc | Prevention et traitement de troubles somatiques fonctionnels, y-compris les troubles lies au stress |
| US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| AU2003239455A1 (en) * | 2002-05-14 | 2003-12-02 | Ralph Ryback | Method for treating dermatoses and tissue damage |
| CA2485466A1 (fr) * | 2002-05-15 | 2003-11-27 | Abbott Laboratories | Traitement de la douleur neuropathique |
| KR20060013632A (ko) | 2002-05-17 | 2006-02-13 | 오쎄라 파마슈티걸즈, 인크. | 백내장 및 다른 안질환 발병의 개선 |
| JP2006509735A (ja) * | 2002-10-17 | 2006-03-23 | ノバルティス アクチエンゲゼルシャフト | オクスカルバゼピンまたはその誘導体およびｃｏｘ２インヒビターからなる疼痛処置用医薬組成物 |
| EP2412719A1 (fr) | 2002-12-02 | 2012-02-01 | Xenome Ltd | Pptides de chi-conotoxine |
| ES2383358T3 (es) | 2002-12-02 | 2012-06-20 | Xenome Ltd | Péptidos de chi-conotoxina que tienen un ácido piroglutámico N-terminal |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| ES2285233T3 (es) | 2002-12-20 | 2007-11-16 | Niconovum Ab | Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable. |
| EP1599221B1 (fr) * | 2003-03-06 | 2011-12-28 | Botulinum Toxin Research Associates, Inc. | Traitement des cephalees et des douleurs faciales chroniques associees a la sinusite au moyen de toxine botulinique |
| NZ542887A (en) * | 2003-04-08 | 2008-05-30 | Algorx Pharmaceuticals Inc | Preparation and purification of synthetic capsaicin |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| WO2004105690A2 (fr) * | 2003-05-23 | 2004-12-09 | Cypress Bioscience, Inc. | Traitement de douleurs chroniques au moyen de chimiotherapie ou de radiotherapie |
| WO2005000806A2 (fr) | 2003-06-10 | 2005-01-06 | Georgetown University | Ligands pour les recepteurs de l'acetylcholine nicotinique, et procedes de production et d'utilisation de ces ligands |
| US20050004221A1 (en) * | 2003-07-01 | 2005-01-06 | Medtronic, Inc. | Intrathecal gabapentin compositions |
| US20050004219A1 (en) * | 2003-07-01 | 2005-01-06 | Medtronic, Inc. | Pump systems including injectable gabapentin compositions |
| US20050043406A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US20050058696A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| EP1689401A1 (fr) | 2003-10-02 | 2006-08-16 | Elan Pharmaceuticals, Inc. | Methode de soulagement de la douleur |
| US20050090549A1 (en) * | 2003-10-23 | 2005-04-28 | Medtronic, Inc. | Intrathecal gabapentin for treatment of pain |
| US20050090548A1 (en) * | 2003-10-23 | 2005-04-28 | Medtronic, Inc. | Intrathecal gabapentin for treatment of epilepsy |
| EP1696877A4 (fr) * | 2003-11-13 | 2010-06-09 | Gen Hospital Corp | Methodes pour traiter la douleur |
| US8871224B2 (en) * | 2003-12-09 | 2014-10-28 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
| HU230403B1 (hu) * | 2003-12-19 | 2016-04-28 | Pál Kocsis | Nátrium csatorna blokkoló és szerotonin újrafelvétel gátló tartalmú gyógyszerkészítmény |
| US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
| CA2569964A1 (fr) * | 2004-06-10 | 2005-12-29 | Duramed Pharmaceuticals, Inc. | Formulations de sumatriptan absorbables au travers des membranes biologiques, et methodes de production et d'utilisation desdites formulations |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| AU2005299748B2 (en) * | 2004-10-21 | 2009-04-09 | Tgel Bio Co., Ltd | In situ controlled release drug delivery system |
| WO2006053012A2 (fr) * | 2004-11-10 | 2006-05-18 | Trinity Laboratories, Inc. | Nouvelles compositions pharmaceutiques destinees a traiter la douleur chronique acquise et la dysphorie associee |
| EP1827405A2 (fr) * | 2004-11-24 | 2007-09-05 | Algorx Pharmaceuticals, Inc. | Formulation a base de capsaicinoide en gel et utilisations afferentes |
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| AU2006249577A1 (en) | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
| US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US20090176882A1 (en) * | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| WO2007104573A2 (fr) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Composition améliorée de tabac à priser |
| JP2007308403A (ja) * | 2006-05-17 | 2007-11-29 | Kenji Yoshida | 皮膚外用剤 |
| JP2009537635A (ja) | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
| CN101074935B (zh) * | 2006-05-19 | 2011-03-23 | 清华大学 | 探测器阵列及设备 |
| FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
| AU2007274583B2 (en) * | 2006-07-17 | 2012-11-01 | Bar-Ilan University | Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders |
| WO2008020651A1 (fr) * | 2006-08-17 | 2008-02-21 | Kyushu University, National University Corporation | antagoniste de récepteur P2X4 |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| US7645767B2 (en) * | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| US20080119820A1 (en) * | 2006-09-20 | 2008-05-22 | Phan Phillip C | Methods for Delivering Volatile Anesthetics for Regional Anesthesia and/or Pain Relief |
| WO2008073381A2 (fr) * | 2006-12-11 | 2008-06-19 | University Of Kentucky Research Foundation | Effets synergiques d'associations de nornicotine et d'opioïdes contre la douleur |
| FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| US8822498B2 (en) | 2007-09-13 | 2014-09-02 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof |
| EP2381834A2 (fr) * | 2008-01-31 | 2011-11-02 | Fund for Medical Research Development of Infrastructure & Health Services Rambam Medical Center | Procédé de prédiction d'efficacité d'analgésique |
| FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
| EP2273880B1 (fr) * | 2008-04-28 | 2014-12-31 | Zogenix, Inc. | Compositions inedites destinees au traitement de la migraine |
| CA2729056A1 (fr) | 2008-06-23 | 2010-01-21 | Janssen Pharmaceutica Nv | Forme cristalline de (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| US20100184685A1 (en) * | 2009-01-19 | 2010-07-22 | Zavala Jr Gerardo | Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein |
| AR081931A1 (es) | 2010-06-15 | 2012-10-31 | Gruenenthal Gmbh | Combinacion farmaceutica |
| WO2012038963A1 (fr) | 2010-09-22 | 2012-03-29 | Ramot At Tel-Aviv University Ltd. | Sel d'addition d'acide d'un conjugué nortriptyline-gaba et son procédé de préparation |
| SG191288A1 (en) | 2010-12-22 | 2013-07-31 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
| JP5638151B2 (ja) | 2010-12-23 | 2014-12-10 | パーデュー、ファーマ、リミテッド、パートナーシップ | 不正加工抵抗性の（ｔａｍｐｅｒｒｅｓｉｓｔａｎｔ）固形経口剤形 |
| BR112013020802A2 (pt) * | 2011-02-18 | 2016-10-04 | Nestec Sa | métodos e composições para tratar, reduzir ou impedir dano ao sistema nervoso de animais |
| ES2387973B1 (es) * | 2011-03-18 | 2013-10-01 | Dr Healthcare España, S. L. | Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor. |
| US8580850B2 (en) | 2011-08-11 | 2013-11-12 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use |
| SG11201501130PA (en) * | 2012-08-16 | 2015-04-29 | Janssen Pharmaceutica Nv | Substituted pyrazoles as n-type calcium channel blockers |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| JP6371463B2 (ja) | 2014-07-17 | 2018-08-08 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 即時放出性乱用抑止性液体充填剤形 |
| EP3209282A4 (fr) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Forme galénique anti-abus de remplissage de liquide à libération prolongée |
| CN104758933A (zh) * | 2014-10-29 | 2015-07-08 | 吴鑫欣 | 治疗神经卡压、神经瘤疼痛的药物和给药系统 |
| CA3057304A1 (fr) * | 2017-03-22 | 2018-09-27 | Bonti, Inc. | Neurotoxines de botulinum pour le traitement de lesions traumatiques |
| US20180280294A1 (en) * | 2017-03-31 | 2018-10-04 | Depco, Inc. | Therapeutic putty having analgesics and/or counterirritants |
| US10463638B2 (en) * | 2017-04-12 | 2019-11-05 | Synergistic Therapeutics, Llc | Therapeutic neuropathic pain lotion |
| KR101944113B1 (ko) | 2017-09-28 | 2019-01-30 | 동의대학교 산학협력단 | 급성 안면통증 예방 및 개선용 조성물 |
| KR102156627B1 (ko) | 2018-12-20 | 2020-09-16 | 동의대학교 산학협력단 | 보스웰리아 추출물 및 산자나무 추출물을 포함하는 급성 안면통증 예방 및 개선용 조성물 |
| KR102156438B1 (ko) | 2018-12-20 | 2020-09-16 | 동의대학교 산학협력단 | 급성 안면통증 예방 및 개선용 조성물 |
| CN115054601B (zh) * | 2022-03-21 | 2024-04-26 | 中山大学附属第三医院 | 一种可注射的缓释镇痛复合物及其制备方法、应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235734B1 (en) * | 1996-10-30 | 2001-05-22 | Pfizer Inc | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy |
| EP0955301A3 (fr) * | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | Dérivés de 7-aza-bicyclo[2.2.1]-heptane, leur préparation et utilisation sur la base d'affinité pour les recepteurs de l'acetylcholine nicotinique neuronaux |
| EA003669B1 (ru) * | 1998-04-29 | 2003-08-28 | Пфайзер Продактс Инк. | Конденсированные с арилом азаполициклические соединения |
| IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
-
2000
- 2000-12-18 US US09/740,307 patent/US20010036943A1/en not_active Abandoned
-
2001
- 2001-03-16 AP APAP/P/2002/002642A patent/AP2002002642A0/en unknown
- 2001-03-16 PL PL01365957A patent/PL365957A1/xx not_active Application Discontinuation
- 2001-03-16 EP EP01910097A patent/EP1272218B1/fr not_active Expired - Lifetime
- 2001-03-16 CA CA002405142A patent/CA2405142A1/fr not_active Abandoned
- 2001-03-16 SK SK1395-2002A patent/SK13952002A3/sk not_active Application Discontinuation
- 2001-03-16 OA OA1200200304A patent/OA12241A/en unknown
- 2001-03-16 MX MXPA02009817A patent/MXPA02009817A/es unknown
- 2001-03-16 JP JP2001574094A patent/JP2003530345A/ja active Pending
- 2001-03-16 YU YU74602A patent/YU74602A/sh unknown
- 2001-03-16 AT AT01910097T patent/ATE291438T1/de not_active IP Right Cessation
- 2001-03-16 IL IL15207601A patent/IL152076A0/xx unknown
- 2001-03-16 EA EA200200910A patent/EA004930B1/ru not_active IP Right Cessation
- 2001-03-16 HU HU0301822A patent/HUP0301822A3/hu unknown
- 2001-03-16 CN CNA01816840XA patent/CN1468111A/zh active Pending
- 2001-03-16 AU AU37680/01A patent/AU3768001A/en not_active Abandoned
- 2001-03-16 KR KR1020027013380A patent/KR20030040201A/ko not_active Application Discontinuation
- 2001-03-16 CZ CZ20023214A patent/CZ20023214A3/cs unknown
- 2001-03-16 ES ES01910097T patent/ES2236185T3/es not_active Expired - Lifetime
- 2001-03-16 EE EEP200200579A patent/EE200200579A/xx unknown
- 2001-03-16 WO PCT/IB2001/000391 patent/WO2001076576A2/fr not_active Application Discontinuation
- 2001-03-16 DE DE60109589T patent/DE60109589T2/de not_active Expired - Fee Related
- 2001-03-16 BR BR0109837-3A patent/BR0109837A/pt not_active IP Right Cessation
- 2001-04-05 PE PE2001000319A patent/PE20011307A1/es not_active Application Discontinuation
- 2001-04-05 GT GT200100055A patent/GT200100055A/es unknown
- 2001-04-05 AR ARP010101625A patent/AR027773A1/es not_active Application Discontinuation
- 2001-04-06 TN TNTNSN01053A patent/TNSN01053A1/fr unknown
- 2001-04-06 SV SV2001000377A patent/SV2002000377A/es not_active Application Discontinuation
- 2001-04-09 PA PA20018515001A patent/PA8515001A1/es unknown
-
2002
- 2002-09-20 IS IS6560A patent/IS6560A/is unknown
- 2002-09-23 BG BG107138A patent/BG107138A/xx unknown
- 2002-10-02 MA MA26846A patent/MA26889A1/fr unknown
- 2002-10-02 CR CR6767A patent/CR6767A/es unknown
- 2002-10-02 NO NO20024734A patent/NO20024734D0/no not_active Application Discontinuation
- 2002-10-04 ZA ZA200207996A patent/ZA200207996B/en unknown
-
2003
- 2003-01-21 US US10/348,381 patent/US20030133951A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200207996B (en) | A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines. | |
| RU2135179C1 (ru) | Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений | |
| AU2008271026A1 (en) | A drug demonstrating anxiolytic effect based on hydrogenated pyrido (4, 3-B) indoles, its pharmacological compound and application method | |
| BRPI0620234A2 (pt) | combinação farmacêutica para o tratamento de luts que compreende um inibidor da pde5 e um antagonista muscarìnico | |
| OA12554A (en) | Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders. | |
| US20030109544A1 (en) | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | |
| NZ506020A (en) | Use of pharmaceutical combinations containing tramadol and an antiemetic | |
| KR20220113411A (ko) | KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도 | |
| CZ2004524A3 (cs) | Agonisté nikotinového acetylcholinového receptoru v léčbě syndromu neklidných nohou | |
| Hegde et al. | To market, to market—2004 | |
| EP1159970A2 (fr) | Composition pharmaceutique destinée au traitement de l'obésité ou favorisant la perte de poids, contenant un agoniste partiel du récepteur à la nicotine et un agent anti-obésité | |
| US20050043407A1 (en) | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | |
| US20040001895A1 (en) | Combination treatment for depression and anxiety | |
| US20050043406A1 (en) | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | |
| JP2008524176A (ja) | ジヒドロイミダゾピラジン誘導体を含む鎮痛性組合せ物 | |
| NZ522478A (en) | Pharmaceutical compositon for the prevention and treatment of nicotine addiction in a mammal | |
| Reuter et al. | Lasmiditan hydrochloride |